ArticleCureus2025

Verification of the Short-Term Impact of Imeglimin on Liver Fibrosis Markers Stratified by Liver Fibrosis Risk in Patients With Type 2 Diabetes.

Takumi Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.